genic chemical groups free to mediate various allergic responses.
Abstract
During 1980-7, 23 pregnancies of 22-38 weeks' duration were investigated for fetal tachycardia. Twelve were cases of supraventricular tachycardia, eight of atrial flutter, and three cases in which the rhythm varied between supraventricular tachycardia and atrial flutter. In 11 cases the fetus had developed non-immune fetal hydrops before referral; 12 cases were non-hydropic at referral but one of this group of fetuses became hydropic during treatment. No relation was found between the rate or type of arrhythmia and the presence or absence of intrauterine heart failure.
One non-hydropic infant was delivered electively prematurely. Maternal antiarrhythmic treatment was instituted in the remaining 22 cases. Conversion of the arrhythmia was achieved with digoxin alone in five cases and with a combination of digoxin and verapamil in nine. Control of the arrhythmia was achieved in seven of the 10 non-hydropic fetuses, and all were delivered at term with no deaths. Of the 12 hydropic fetuses, control was achieved in seven. Only three of the hydropic fetuses were delivered close to term. There were two deaths, both in the hydropic group. Of the whole group, five neonates suffered severe complications of prematurity.
In this series the main benefit of treatment appeared to be in prolonginggestation ofthose hydropic fetuses in which conversion was achieved. 
Results
Table I summarises the clinical details and outcome of treatment of the fetuses that were not in heart failure BMJ VOLUME 297 
the type of arrhythmia and the heart rate is not supported by our data, as we found no difference between the hydropic and non-hydropic groups in either of these features. A factor which may be important is the duration of the arrhythmia and its intermittent nature. Three fetuses were in sinus rhythm at the initial examination after referral for fetal hydrops. All were found to have a tachycardia at a later examination. Two are not included in this series, as they were sent back to the referring hospital before the diagnosis of intermittent tachycardia was made and were therefore not treated by us. The possibility of an intermittent tachycardia as a cause of fetal hydrops must be considered and the mother admitted for fetal heart rate monitoring. Doppler cardiotocography is unreliable and misleading for this and we have used phonocardiography'3 for prolonged (12-24 hour) recording.
Based on experience we treat all hydropic fetuses with the mothers as inpatients. Non-hydropic fetuses may be treated in the outpatient department and delivered safely in local centres once conversion has been achieved. We chose digoxin as the most practicable treatment because of its known safety in pregnancy. Verapamil was added in refractory cases for its additive effect with digoxin. There appeared to be no maternal or fetal morbidity attributable to treatment. We achieved conversion to sinus rhythm in 14 of 22 patients overall, and in a further three partial control was achieved. These results are comparable with other series. 8 In three of five cases in which control was not achieved delivery took place less than a week after the start of antiarrhythmic drugs, before adequate treatment could be given. A further case in this group was not treated fully according to our regimen because of poor maternal compliance.
Sequential maternal serum drug concentrations during treatment coupled with cord blood sampling has allowed us to begin to understand placental transfer of these drugs. Many workers have reported failure of digoxin and verapamil and have tried various other drugs, such as procainamide, quinidine, and amiodarone.6-8 We, however, find that high doses given for two to three weeks are necessary to achieve rhythm control, particularly in hydropic fetuses. Our results of fetal blood sampling from the umbilical cord under ultrasound control and of cord blood sampling at delivery compared with simultaneous maternal sampling indicate that placental transfer of digoxin is around 40% and of verapamil of the order of 10-20%. With the exception of the one case which progressed from the non-hydropic to the hydropic group, analysis of the outcome in the non-hydropic group does not show a clear advantage to the fetus of successful treatment. All 11 cases were delivered at term irrespective of rhythm control in utero. In all three cases in which complete control had not been achieved prenatally, however, difficulty was experienced in gaining control postnatally.
All the patients in the hydropic group required both digoxin and verapamil and, on average, a longer duration of treatment to achieve conversion. In this group where control was achieved reversal of the ascites took many days or even weeks after return to sinus rhythm. Mortality and morbidity occurred whether control, partial control, or no control was achieved. It appears that prolongation of gestation occurred after successful treatment. The absence of a control group of untreated cases does not allow us to conclude that treatment caused this delay in delivery. Nevertheless, our results suggest that premature delivery, whether spontaneous or induced, should be BMJ VOLUME 297 9 JULY 1988 avoided. Our one experience with direct fetal treatment was not successful, and possibly a longer duration of transplacental treatment would have been more appropriate.
In our series the Wolff-Parkinson-White syndrome as the underlying cause of the tachycardia was found in three of the 22 infants who had a postnatal electrocardiogram.
In summary p, ,hological atrial tachycardias are a potential cause of non-immune hydrops. As these rhythm disturbances may be intermittent, this diagnosis should be considered in all cases of fetal hydrops even if the tachycardia is not present at the initial examination. It is not possible to predict which of the non-hydropic fetuses will progress to become hydropic. We In most patients receiving cisplatin nausea and vomiting are observed one to six hours after the drug is given and last for up to 10 days'; currently available antiemetics show limited efficacy. At conventional doses metoclopramide is inactive, but at high doses it is effective against the vomiting induced by cisplatin, although extrapyramidal reactions are observed.2 At these doses metoclopramide competitively blocks serotonin type 3 receptors.3 Selective serotonin type 3 receptor antagonists exhibit potent antiemetic activity in ferrets and recently GR 38032F was shown to be effective in patients receiving mildly emetic drugs,
